Search

everythinglearnresearchcommunity

for

Search:↓

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

Ion sequential therapy improves heart function after a heart attack.

Healthcare claims databases can help monitor drug safety, but may report adverse events differently than direct surveillance.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

KB2115 (eprotirome) can safely extend the hair growth phase without damaging cells or changing hair color.

Prostaglandin E2 helps prevent hair loss from radiotherapy by protecting hair cells.

The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.

Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

Injecting 2 ml of TEEV every 4 weeks is better because it has the same benefits but fewer side effects.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

The combination treatment showed a higher response rate but no significant survival benefits.

Engineered extracellular vesicles show promise for targeted therapy but need more research for clinical use.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

EV-based drug delivery shows promise but faces challenges in standardization and scalability.